Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

SUMO2 anticorps

L’anticorps Souris Monoclonal anti-SUMO2 a été validé pour IF, FACS et IHC (f). Il convient pour détecter SUMO2 dans des échantillons de Humain.
N° du produit ABIN6938469

Aperçu rapide pour SUMO2 anticorps (ABIN6938469)

Antigène

Voir toutes SUMO2 Anticorps
SUMO2 (Small Ubiquitin Related Modifier 2 (SUMO2))

Reactivité

  • 101
  • 40
  • 36
  • 3
  • 2
  • 1
  • 1
  • 1
Humain

Hôte

  • 80
  • 25
  • 1
Souris

Clonalité

  • 81
  • 26
Monoclonal

Conjugué

  • 57
  • 9
  • 8
  • 7
  • 5
  • 5
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp SUMO2 est non-conjugé

Application

  • 71
  • 53
  • 38
  • 21
  • 13
  • 11
  • 11
  • 8
  • 6
  • 5
  • 4
  • 2
  • 1
  • 1
Immunofluorescence (IF), Flow Cytometry (FACS), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))

Clone

SUMO2-1199
  • Specificité

    The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, 2 and 3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include MDM2, p53, PML and RanGap1. SUMO-2 and 3 contribute to a greater percentage of protein modification than does SUMO-1 and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease.

    Réactivité croisée (Details)

    Human. Rat. Predicted to show a broad species reactivity.

    Purification

    1.0mg/ml of Ab purified from Bioreactor by Protein A/G.

    Immunogène

    Recombinant human SUMO2 protein

    Isotype

    IgG1 kappa
  • Indications d'application

    Known_Application: Flow Cytometry (1-2 μg/million cells), Immunofluorescence (1-2 μg/mL), Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT)(Staining of formalin-fixed tissues requires heating tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 45 min at 95°C followed by cooling at RT for 20 minutes), Optimal dilution for a specific application should be determined.

    Positive_Control: HeLa cells. Breast carcinoma.

    Restrictions

    For Research Use only
  • Concentration

    1.0 mg/mL

    Buffer

    Prepared in 10 mM PBS, WITHOUT BSA and Azide.

    Agent conservateur

    Azide free

    Stock

    -20 °C,-80 °C

    Stockage commentaire

    Antibody without azide store at -20 to -80 °C. Antibody is stable for 24 months. Non-hazardous.

    Date de péremption

    24 months
  • Antigène

    SUMO2 (Small Ubiquitin Related Modifier 2 (SUMO2))

    Autre désignation

    SUMO2

    Sujet

    HSMT3, Sentrin 2, Small ubiquitin like modifier 2, Small ubiquitin like modifier protein 3, SMT3A, SMT3B, SMT3 homolog 1 (SMT3H1), SMT3 homolog 2 (SMT3H2), SMT3 homolog, SMT3 suppressor of mif two 3 homolog 1, SMT3 suppressor of mif two 3 homolog 2, SMT3 suppressor of mif two 3 homolog 3, Suppressor of mif two 3 homolog 2, Suppressor of mif two 3 homolog 3, Ubiquitin like protein SMT3A, Ubiquitin like protein SMT3B,SUMO-2
    Cellular localisation: Nuclear

    Poids moléculaire

    11-13kDa

    ID gène

    6613, 474005

    UniProt

    P55854

    Pathways

    Methionine Biosynthetic Process
Vous êtes ici:
Chat with us!